Insider Selling: Karyopharm Therapeutics Inc. (KPTI) SVP Sells $55,777.50 in Stock

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) SVP Christopher Brett Primiano sold 4,958 shares of the business’s stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total transaction of $55,777.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Christopher Brett Primiano also recently made the following trade(s):

  • On Monday, October 2nd, Christopher Brett Primiano sold 1,500 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $12.00, for a total transaction of $18,000.00.
  • On Friday, September 15th, Christopher Brett Primiano sold 2,000 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $11.00, for a total transaction of $22,000.00.
  • On Tuesday, August 29th, Christopher Brett Primiano sold 2,195 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $10.00, for a total transaction of $21,950.00.

Shares of Karyopharm Therapeutics Inc. (KPTI) opened at $10.91 on Friday. Karyopharm Therapeutics Inc. has a 52 week low of $7.48 and a 52 week high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. equities analysts anticipate that Karyopharm Therapeutics Inc. will post -2.58 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Karyopharm Therapeutics Inc. (KPTI) SVP Sells $55,777.50 in Stock” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/12/insider-selling-karyopharm-therapeutics-inc-kpti-svp-sells-55777-50-in-stock.html.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Swiss National Bank increased its stake in Karyopharm Therapeutics by 39.2% during the 2nd quarter. Swiss National Bank now owns 56,850 shares of the company’s stock worth $514,000 after buying an additional 16,000 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Karyopharm Therapeutics by 4.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock worth $1,111,000 after buying an additional 3,762 shares during the period. Teachers Advisors LLC increased its stake in Karyopharm Therapeutics by 2.6% during the 2nd quarter. Teachers Advisors LLC now owns 431,350 shares of the company’s stock worth $3,904,000 after buying an additional 10,787 shares during the period. Geode Capital Management LLC increased its stake in Karyopharm Therapeutics by 7.8% during the 1st quarter. Geode Capital Management LLC now owns 168,770 shares of the company’s stock worth $2,167,000 after buying an additional 12,277 shares during the period. Finally, Vanguard Group Inc. increased its stake in Karyopharm Therapeutics by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 1,236,762 shares of the company’s stock worth $15,880,000 after buying an additional 110,093 shares during the period. 59.14% of the stock is currently owned by hedge funds and other institutional investors.

KPTI has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. ValuEngine downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 31st. Royal Bank Of Canada initiated coverage on shares of Karyopharm Therapeutics in a research note on Thursday, September 14th. They issued an “outperform” rating and a $14.00 price target on the stock. Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 12th. Finally, BidaskClub raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $15.50.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply